Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial

Collection UNKNOWN
G. Kremsner, Peter; A. Adegnika, Akim; B. Hounkpatin, Aurore; F. Zinsou, Jeannot; E. Taylor, Terrie; Chimalizeni, Yamikani; Liomba, Alice; Kombila, Maryvonne; K. Bouyou-Akotet, Marielle; P. Mawili Mboumba, Denise; Agbenyega, Tsiri; Ansong, Daniel; Sylverken, Justice; R. Ogutu, Bernhards; A. Otieno, Godfrey; Wangwe, Anne; A. Bojang, Kalifa; Okomo, Uduak; Sanya-Isijola, Frank; R. Newton, Charles; Njuguna, Patricia; Kazungu, Michael; Kerb, Reinhold; Geditz, Mirjam; Schwab, Matthias; P. Velavan, Thirumalaisamy; Nguetse, Christian; Köhler, Carsten; Issifou, Saadou; Bolte, Stefanie; ... view all 33 authors
(2016)
  • Publisher: Figshare
  • Related identifiers: doi: 10.1371/journal.pmed.1001938
  • Subject: Uncategorised | N 86YPfmdr genotype | Multicenter Randomized Controlled Trial BackgroundCurrent artesunate | PACTR | parenteral ARS regimen | parasite clearance kinetics | i.v | i.m | African children.Trial registrationPan | ci | 24 h | analysis

<div><p>Background</p><p>Current artesunate (ARS) regimens for severe malaria are complex. Once daily intramuscular (i.m.) injection for 3 d would be simpler and more appropriate for remote health facilities than the current WHO-recommended regimen of five intravenous (... View more
Share - Bookmark

  • Download from
    figshare via figshare (Collection, 2016)
  • Cite this research product